Early disease progression within twelve months of starting initial therapy marks a high-risk subset of patients with mantle cell lymphoma who experience significantly poorer subsequent survival, according to findings from a retrospective multi-center investigation published in Annals of Hematology.

Early progression following first-line therapy has been recognized as an indicator of high-risk mantle cell lymphoma, but its post-progression implications and subsequent treatment patterns have remained incompletely defined in clinical practice.

To evaluate these dynamics, researchers analyzed clinical data from 216 newly diagnosed patients with mantle cell lymphoma who received care across two medical centers in China between 2010 and 2022. In the study framework, progression of disease within 12 months, designated as POD12, was defined as disease progression, relapse, or death occurring within 12 months following the initiation of first-line therapy. The investigators assessed post-progression survival alongside exposure to Bruton tyrosine kinase inhibitors in subsequent lines of therapy.

First-line therapeutic regimens across the cohort were heterogeneous over the twelve-year study window. Among the treated patients, 49.5 percent received R-CHOP-like regimens, 26.9 percent received cytarabine-containing or intensive therapies, 10.6 percent received regimens containing Bruton tyrosine kinase inhibitors, 2.8 percent received bendamustine plus rituximab, and 10.2 percent received other therapeutic regimens.

Among 209 patients evaluable for the POD12 endpoint, 68 individuals (32.5 percent) experienced progression of disease within twelve months. Multivariable analysis demonstrated that elevated baseline lactate dehydrogenase levels (odds ratio, 2.31; 95 percent confidence interval, 1.19 to 4.46; P = 0.01) and a Ki-67 proliferation index of at least 50 percent (odds ratio, 2.37; 95 percent confidence interval, 1.17 to 4.82; P = 0.02) were independently associated with POD12.

Survival analyses revealed significant differences in patient outcomes based on progression timing. In a 12-month landmark cohort analysis, POD12 was independently associated with inferior subsequent overall survival, with a hazard ratio of 5.20 (95 percent confidence interval, 3.13 to 8.63; P < 0.001). Among 123 patients evaluable for post-progression survival, median survival after disease progression was 22.1 months for those progressing at or within 12 months, 42.1 months for those progressing between 12 and 24 months, and not reached for those progressing after 24 months, reflecting an overall log-rank P value of less than 0.001.

Subsequent therapeutic choices also correlated with clinical trajectory, as exposure to Bruton tyrosine kinase inhibitors in subsequent lines of therapy was associated with longer post-progression survival across the cohort (adjusted hazard ratio, 0.23; 95 percent confidence interval, 0.13 to 0.38) and among patients who experienced POD12 (adjusted hazard ratio, 0.24; 95 percent confidence interval, 0.12 to 0.46). The authors noted that while POD12 identifies high-risk patients and subsequent inhibitor exposure is associated with improved post-progression survival, these observational associations should not be interpreted as causal relationships.

Subject of Research: Early disease progression and post-progression survival in mantle cell lymphoma

Article Title: POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure

Article References: Chai, J., Lei, X., Song, Y., & Yu, H. (2026). POD12 in mantle cell lymphoma: comparison with POD24, post-progression survival, and BTK inhibitor exposure. Annals of Hematology. https://doi.org/10.1007/s00277-026-07352-y

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07352-y

Keywords: mantle cell lymphoma, POD12, POD24, post-progression survival, Bruton tyrosine kinase inhibitor, BTKi therapy, lactate dehydrogenase, Ki-67 index, R-CHOP, cytarabine, bendamustine, rituximab, first-line therapy, landmark analysis, disease progression, hematologic oncology, Annals of Hematology